Cardiac Myosin Activator Omecamtiv Mecarbil: Novel Treatment for Systolic Heart Failure.
| Autor: | Mack M; From the Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY., Frishman WH |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiology in review [Cardiol Rev] 2024 Jul-Aug 01; Vol. 32 (4), pp. 378-383. Date of Electronic Publication: 2023 Mar 22. |
| DOI: | 10.1097/CRD.0000000000000530 |
| Abstrakt: | Systolic Heart failure is a complex clinical syndrome characterized by a decrease in cardiac contractility and a reduction in organ perfusion. Current pharmacologic inotropes attempt to improve contractility via indirect mechanisms but are limited in terms of safety and effectiveness. Omecamtiv mecarbil is a novel agent in a new class of drugs known as cardiac myosin activators; their unique mechanism of action involves directly activating the enzymatic pathway in the cardiac myocyte as a way to improve ventricular contraction. Preclinical and clinical trials have found that omecamtiv mecarbil improves cardiac contractility without increasing the risk of any of the harmful effects that are associated with the currently available inotropic agents. Omecamtiv mecarbil is a worthwhile advance and patients with systolic heart failure would benefit from pharmacological use of this drug. Competing Interests: Disclosure: The authors have no conflict of interest to report. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|